Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
temozolomide
Merck Sharp & Dohme B.V.
L01AX03
temozolomide
Antineoplastic agents
Glioma; Glioblastoma
Temodal hard capsules is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Revision: 37
Authorised
1999-01-26
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PROD UCT Temodal 5 mg hard capsules Temodal 20 mg hard capsules Temodal 100 mg hard capsu les Temodal 140 mg hard capsules Temodal 180 mg hard capsules Temodal 250 mg hard capsules 2. QUALITATIVE AND QU ANTITATIVE COMPOSITION 5 mg hard capsules Each hard capsu le contains 5 mg temozolomide. Excipient(s) with known effe ct: Ea ch hard capsule contains 132.8 mg of anhydrous lactose. 20 mg hard capsules Each hard cap sule contains 20 mg temozolomide. Excipient(s) with known effect: Each hard capsule contains 182.2 mg of anhyd rous lactose. 100 mg hard capsules Each hard capsule contains 100 mg temozolomide. Excipient(s) with known effect: Each hard capsule contains 175.7 mg of anhydrous lactose. 140 mg ha rd capsules Each hard capsule contains 140 mg temozolomide . Excipient(s) with known effect: Each hard capsule contains 246 mg of anhydrous lactose. 180 mg hard capsules Each hard capsule contains 180 mg temozolo mide. Excipient(s) with known effe ct: E ach hard capsule contains 316.3 mg of anhydrous lactose. 250 mg hard capsules Each hard capsule contains 250 mg temozolomide. Excipient(s) with known effect : Each hard capsule contains 154.3 mg of anhydrous lacto se. For the full list of excipient s, see section 6.1. 3. PHARMACEUTICAL FORM 5 mg hard capsule (capsule). The hard capsules have an opaque white body, an opaque green cap, and are imprinted w ith black ink. The cap is imprinted with “ TEMODAL ”. T he body is imprinted with "5 mg", the Sch ering-Plough logo and two stripes. 3 20 mg hard capsule (capsule) The hard capsules have an opaque white body, an opaque yellow cap, and are imprinted with black ink. The cap is imprinted with “ TEMODAL ”. The body is impri n ted with "20 mg", the Schering - Plough lo go and two stripes. 100 mg hard capsul e (capsule) The hard capsules have an opaque white body, an opaque pink cap, and are imprinted with black in k. The cap is imprinted with “ TEMODAL ”. The bod y is imprinted with "100 m Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PROD UCT Temodal 5 mg hard capsules Temodal 20 mg hard capsules Temodal 100 mg hard capsu les Temodal 140 mg hard capsules Temodal 180 mg hard capsules Temodal 250 mg hard capsules 2. QUALITATIVE AND QU ANTITATIVE COMPOSITION 5 mg hard capsules Each hard capsu le contains 5 mg temozolomide. Excipient(s) with known effe ct: Ea ch hard capsule contains 132.8 mg of anhydrous lactose. 20 mg hard capsules Each hard cap sule contains 20 mg temozolomide. Excipient(s) with known effect: Each hard capsule contains 182.2 mg of anhyd rous lactose. 100 mg hard capsules Each hard capsule contains 100 mg temozolomide. Excipient(s) with known effect: Each hard capsule contains 175.7 mg of anhydrous lactose. 140 mg ha rd capsules Each hard capsule contains 140 mg temozolomide . Excipient(s) with known effect: Each hard capsule contains 246 mg of anhydrous lactose. 180 mg hard capsules Each hard capsule contains 180 mg temozolo mide. Excipient(s) with known effe ct: E ach hard capsule contains 316.3 mg of anhydrous lactose. 250 mg hard capsules Each hard capsule contains 250 mg temozolomide. Excipient(s) with known effect : Each hard capsule contains 154.3 mg of anhydrous lacto se. For the full list of excipient s, see section 6.1. 3. PHARMACEUTICAL FORM 5 mg hard capsule (capsule). The hard capsules have an opaque white body, an opaque green cap, and are imprinted w ith black ink. The cap is imprinted with “ TEMODAL ”. T he body is imprinted with "5 mg", the Sch ering-Plough logo and two stripes. 3 20 mg hard capsule (capsule) The hard capsules have an opaque white body, an opaque yellow cap, and are imprinted with black ink. The cap is imprinted with “ TEMODAL ”. The body is impri n ted with "20 mg", the Schering - Plough lo go and two stripes. 100 mg hard capsul e (capsule) The hard capsules have an opaque white body, an opaque pink cap, and are imprinted with black in k. The cap is imprinted with “ TEMODAL ”. The bod y is imprinted with "100 m Przeczytaj cały dokument